ATE410429T1 - Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase - Google Patents

Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase

Info

Publication number
ATE410429T1
ATE410429T1 AT03743361T AT03743361T ATE410429T1 AT E410429 T1 ATE410429 T1 AT E410429T1 AT 03743361 T AT03743361 T AT 03743361T AT 03743361 T AT03743361 T AT 03743361T AT E410429 T1 ATE410429 T1 AT E410429T1
Authority
AT
Austria
Prior art keywords
kinase
bicyclic pyridine
pyrimidine inhibitors
pyrimidine
inhibitors
Prior art date
Application number
AT03743361T
Other languages
English (en)
Inventor
Jian Chen
Nolan Dewdney
Christoph Stahl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE410429T1 publication Critical patent/ATE410429T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT03743361T 2002-03-07 2003-02-28 Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase ATE410429T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36237302P 2002-03-07 2002-03-07
US43050802P 2002-12-03 2002-12-03

Publications (1)

Publication Number Publication Date
ATE410429T1 true ATE410429T1 (de) 2008-10-15

Family

ID=27791709

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03743361T ATE410429T1 (de) 2002-03-07 2003-02-28 Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase

Country Status (19)

Country Link
US (3) US7091347B2 (de)
EP (1) EP1485390B1 (de)
JP (1) JP4187657B2 (de)
KR (1) KR100714519B1 (de)
CN (1) CN100386328C (de)
AR (1) AR038864A1 (de)
AT (1) ATE410429T1 (de)
AU (1) AU2003210388B2 (de)
BR (1) BR0308232A (de)
CA (1) CA2477721A1 (de)
DE (1) DE60323946D1 (de)
ES (1) ES2314224T3 (de)
MX (1) MXPA04008592A (de)
PA (1) PA8568401A1 (de)
PE (1) PE20040189A1 (de)
PL (1) PL372886A1 (de)
RU (1) RU2301233C2 (de)
TW (1) TW200306194A (de)
WO (1) WO2003074530A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE323702T1 (de) 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
JP2007517052A (ja) * 2003-12-23 2007-06-28 ノバルティス アクチエンゲゼルシャフト 二環式ヘテロ環式ｐ−３８キナーゼ阻害剤
PL1713806T3 (pl) 2004-02-14 2013-09-30 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
CN1926139A (zh) * 2004-02-27 2007-03-07 霍夫曼-拉罗奇有限公司 稠合吡唑衍生物
KR20060114022A (ko) 2004-02-27 2006-11-03 에프. 호프만-라 로슈 아게 인다졸 유도체 및 그들을 함유하는 약학 조성물
KR100844864B1 (ko) * 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
BRPI0517272A (pt) 2004-10-29 2008-10-07 Tibotec Pharm Ltd derivados de pirimidina bicìclicos de inibição de hiv
GB0427604D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
JP2009506007A (ja) * 2005-08-25 2009-02-12 エフ．ホフマン−ラ ロシュ アーゲー ｐ３８ＭＡＰキナーゼ阻害剤及びその使用方法
EP2038289A2 (de) * 2006-04-21 2009-03-25 Amgen Inc. Thieno-[2,3-d]pyrimidin- und thieno-pyridazinverbindungen und anwendungsverfahren
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
RU2540074C2 (ru) * 2007-06-21 2015-01-27 Кара Терапеутикс, Инк Производные имидазопиразина или имидазодиазепина, активные в отношении рецептора св2
RU2345996C1 (ru) * 2007-07-17 2009-02-10 Андрей Александрович Иващенко Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
RU2341527C1 (ru) * 2007-07-17 2008-12-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
UY31631A1 (es) 2008-02-06 2009-09-30 Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
TW201002713A (en) 2008-04-09 2010-01-16 Organon Nv Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as PKC-theta inhibitors
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US20130102601A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
CN103254194B (zh) * 2013-05-17 2015-07-08 浙江师范大学 一种8-硫杂黄嘌呤化合物的制备方法
EP4772247A2 (de) 2013-08-14 2026-07-08 Novartis AG Kombinationstherapie zur behandlung von krebs
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
CN106220644B (zh) * 2015-04-24 2020-07-31 广州再极医药科技有限公司 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
US20200325148A1 (en) * 2017-12-21 2020-10-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
EP3728201A1 (de) * 2017-12-21 2020-10-28 Gliapharm SA Zusammensetzungen und verfahren zur behandlung von neurologischen erkrankungen mit demenz

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835157A (en) * 1988-03-15 1989-05-30 Ortho Pharmaceutical Corporation Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
EP0766684A4 (de) 1994-06-09 1997-07-16 Smithkline Beecham Corp Endothelin-rezeptor antagonisten
US6075037A (en) 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
CA2223081C (en) * 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
EP0960102A1 (de) 1996-07-08 1999-12-01 Du Pont Pharmaceuticals Company Amidinoindole, amidinoazole und analoge davon als inhibitoren von thrombin und von faktor xa
WO1998006715A1 (en) * 1996-08-09 1998-02-19 Smithkline Beecham Corporation Novel piperazine containing compounds
EP0923287A4 (de) 1996-08-30 2001-08-01 Lilly Co Eli Nichtklassische pyrrolo(2,3-d)pyrimidin antifolate
HRP20000209A2 (en) * 1997-10-20 2001-04-30 Hoffmann La Roche Bicyclic kinase inhibitors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
HK1052705B (en) * 2000-08-14 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
AU2002333524A1 (en) * 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors

Also Published As

Publication number Publication date
AU2003210388B2 (en) 2007-05-17
US20030207900A1 (en) 2003-11-06
TW200306194A (en) 2003-11-16
PA8568401A1 (es) 2003-12-10
ES2314224T3 (es) 2009-03-16
BR0308232A (pt) 2004-12-28
US7439247B2 (en) 2008-10-21
DE60323946D1 (de) 2008-11-20
PL372886A1 (en) 2005-08-08
CN100386328C (zh) 2008-05-07
US20050288312A1 (en) 2005-12-29
CN1639168A (zh) 2005-07-13
US7091347B2 (en) 2006-08-15
PE20040189A1 (es) 2004-05-01
AU2003210388A1 (en) 2003-09-16
US20060084803A1 (en) 2006-04-20
KR20040091084A (ko) 2004-10-27
AR038864A1 (es) 2005-02-02
CA2477721A1 (en) 2003-09-12
KR100714519B1 (ko) 2007-05-07
US7449472B2 (en) 2008-11-11
JP4187657B2 (ja) 2008-11-26
RU2301233C2 (ru) 2007-06-20
EP1485390B1 (de) 2008-10-08
RU2004129768A (ru) 2005-08-27
MXPA04008592A (es) 2004-12-06
JP2005526057A (ja) 2005-09-02
EP1485390A1 (de) 2004-12-15
WO2003074530A1 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
DE60323946D1 (de) Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase
ATE341546T1 (de) 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine
IS7661A (is) Process for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase
DE60324805D1 (de) Inhibitoren von tyrosinkinasen
EP1490373A4 (de) Inhibitoren von nukleosidphosphorylasen und nukleosidasen
ATE472536T1 (de) Pyridin- und pyrimidin-derivate
DE602004016970D1 (de) P38 inhibitor und anwendungsverfahren dafür
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DE69940115D1 (de) Heterocyclische inhibitoren von p38
PL357502A1 (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
IS7599A (is) Heterósýklískir kínasatálmar
NO20045677D0 (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20051493D0 (no) Imidazolpyridiner og fremgangsmater for fremstilling og anvendelse av de samme
EE200300227A (et) P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendid
NO20021783L (no) Alkylamino-substituerte bicykliske nitrogen-heterocykler som inhibitorer for P38-protein-kinase
ATE339416T1 (de) Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
DE60316581D1 (de) 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
DE60039616D1 (de) INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
PL376374A1 (en) Azaindole derivatives as inhibitors of p38 kinase
ATE298758T1 (de) Kristalline freie base von clindamycin
EP1534268A4 (de) Tyrosin-kinase-hemmer
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
EP1515727A4 (de) (halo-benzo carbonyl)heterobicyclische p38 kinase hemmungsmittel
EP1545528A4 (de) Derivate vom indoltyp als hemmer der p38 kinase
ATE283852T1 (de) Naphthostyril derivate und deren verwendung als inhibitoren von cyclin-abhängigen kinasen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1485390

Country of ref document: EP

REN Ceased due to non-payment of the annual fee